Novel pyrrolo[2,1-f][1,2,4]triazin-4-amines: Dual inhibitors of EGFR and HER2 protein tyrosine kinases

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 2, 2011, Pages 781-785

  Fink, Brian E ^a   Norris, Derek ^a   Mastalerz, Harold ^a   Chen, Ping ^a   Goyal, Bindu ^a   Zhao, Yufen ^a   Kim, Soong Hoon ^a   Vite, Gregory D ^a   Lee, Francis Y ^a   Zhang, Hongjian ^a   Oppenheimer, Simone ^a   Tokarski, John S ^a   Wong, Tai W ^a   Gavai, Ashvinikumar V ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

EGFR; HER2; Kinase inhibitor

Indexed keywords

5 [(4 AMINOPIPERIDIN 1 YL)METHYL]PYRROLO[2,1 F][1,2,4]TRIAZIN 4 AMINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; LIPOPHILICITY; MOLECULAR WEIGHT; NONHUMAN; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLONIC NEOPLASMS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; NEOPLASMS; PROTEIN-TYROSINE KINASES; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TRIAZINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78651250889     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.11.100     Document Type: Article

References (19)

1. N.E. Hynes, and H.A. Lane Nat. Rev. Cancer 5 2005 341
2. J. Baselga, and C.L. Arteaga J. Clin. Oncol. 23 2005 2445
3. D.S. Salomon, R. Brandt, F. Ciardiello, and N. Normanno Crit. Rev. Oncol. Hematol. 19 1995 183
4. B. Moy, P. Kirkpatrick, S. Kar, and P. Goss Nat. Rev. Drug Disc. 6 2007 431
5. T.W. Wong, F.Y. Lee, C. Yu, F.R. Luo, S. Oppenheimer, H. Zhang, R.A. Smykla, H. Mastalerz, B.E. Fink, J.T. Hunt, A.V. Gavai, and G.D. Vite Clin. Cancer Res. 12 2006 6186
6. A.V. Gavai, B.E. Fink, D.J. Fairfax, G.S. Martin, L.M. Rossiter, C.L. Holst, S.-H. Kim, K.J. Leavitt, H. Mastalerz, W.-C. Han, D. Norris, B. Goyal, S. Swaminathan, B. Patel, A. Mathur, D.M. Vyas, J.S. Tokarski, C. Yu, S. Oppenheimer, H. Zhang, P. Marathe, J. Fargnoli, F.Y. Lee, T.W. Wong, and G.D. Vite J. Med. Chem. 52 2009 6527
7. H. Mastalerz, M. Chang, P. Chen, B.E. Fink, A. Gavai, W-C. Han, W. Johnson, D. Langley, F.Y. Lee, K. Leavitt, P. Marathe, D. Norris, S. Oppenheimer, B. Sleczka, J. Tarrant, J.S. Tokarski, G.D. Vite, D.M. Vyas, H. Wong, T.W. Wong, H. Zhang, and G. Zhang Bioorg. Med. Chem. Lett. 17 2007 4947
8. H. Mastalerz, M. Chang, P. Chen, P. Dextraze, B.E. Fink, A. Gavai, B. Goyal, W.-C. Han, W. Johnson, D. Langley, F.Y. Lee, P. Marathe, A. Mathur, S. Oppenheimer, E. Ruediger, J. Tarrant, J.S. Tokarski, G.D. Vite, D.M. Vyas, H. Wong, T.W. Wong, H. Zhang, and G. Zhang Bioorg. Med. Chem. Lett. 17 2007 2036
9. Gavai, A. V.; Han, W.-C.; Chen, P.; Ruediger, E. H.; Mastalerz, H.; Fink, B. E.; Norris, D. J. PCT Int. Appl. WO 2005065266, 2005; 83.
10. H. Mastalerz, M. Chang, A. Gavai, W. Johnson, D. Langley, F.Y. Lee, P. Marathe, A. Mathur, S. Oppenheimer, J. Tarrant, J.S. Tokarski, G.D. Vite, D.M. Vyas, H. Wong, T.W. Wong, H. Zhang, and G. Zhang Bioorg. Med. Chem. Lett. 17 2007 2828
11. B. Fink, G.D. Vite, H. Matalerz, J. Kadow, S.-H. Kim, K. Leavitt, K. Du, D. Crews, T. Mitt, T.-W. Wong, J. Hunt, D. Vyas, and J. Tokarski Bioorg. Med. Chem. Lett. 15 2005 4774
12. S. Cockerill, C. Stubberfield, J. Stables, M. Carter, S. Guntrip, K. Smith, S. McKeown, R. Shaw, P. Topley, L. Thomsen, K. Affleck, A. Jowett, D. Hayes, M. Willson, P. Woolard, and D. Spalding Bioorg. Med. Chem. Lett. 11 2001 1401
13. D.W. Rusnak, K. Affleck, S.G. Cockerill, C. Stubberfield, R. Harris, M. Page, K.J. Smith, S.B. Guntrip, M.C. Carter, R.J. Shaw, A. Jowett, J. Stables, P. Topley, E.R. Wood, P.S. Brignola, S.H. Kadwell, B.R. Reep, R.J. Mullin, K.J. Alligood, B.R. Keith, R.M. Crosby, D.M. Murray, W.B. Knight, T.M. Gilmer, and K. Lackey Cancer Res. 61 2001 7196
14. E.R. Wood, A.T. Truesdale, O.B. McDonald, D. Yuan, A. Hassel, S.H. Dickerson, B. Ellis, C. Pennisi, E. Horne, K. Lackey, K.J. Alligood, D.W. Rusnak, T.M. Gilmer, and L. Shewchuk Cancer Res. 64 2004 6652
15. Stamos, J.; Slikowski, C.; Eigenbrot, C. J. Biol. Chem. 2002, 277, 46,265. Molsoft modeling software was used to produce this figure. Molsoft LLC, 3366 No. Torrey Pines Ct., Ste. 300, La Jolla, CA 92037.
16. 6) δ 9.6 (s, 1H, NH).
17. S.K. Bhattacharya, E.D. Cox, J.C. Kath, A.M. Mathiowetz, J. Morris, J.D. Moyer, L.R. Pustilnik, D.T. Rafidi, C. Su, and M.D. Wessel Biochem. Biophys. Res. Commun. 307 2003 267
18. The free fraction (fu) for 8l and 3 were 1.2% and 2.6%, respectively, as determined by equilibrium dialysis at 10 μM.
19. Tumors were excised and homogenized in a glass homogenizer using a buffer that contained 1% Triton X-100, 40 mM Tris-HCl (pH 7.7), 10% glycerol, 1 mM EDTA, 0.15 M NaCl, 1 mM sodium vanadate, and 40 μM ammonium molybdate. Tumor lysates were centrifuged at 12,000×g for 10 min and the supernatants were saved. Since the HER2 gene is amplified in N87 tumors, receptor phosphorylation was readily quantitated by western blot analyzes using tumor lysates directly. Tumor lysates (50 μg proteins) were fractionated by gel electrophoresis and western blot analysis was carried out using anti-phosphotyrosine antibody (PY20, Invitrogen), and anti-HER2 antibody (see Ref. 4b). HER2 receptor phosphorylation was quantified by densitometry and normalized against HER2 receptor levels.